لخّصلي

The preferred solid dosage form for mebeverine is typically a sustained-release capsule.Rationale for Sustained-Release Capsules

o	Controlled Release:

Mebeverine is an antispasmodic used primarily for the treatment of irritable bowel syndrome (IBS) and other gastrointestinal disorders.A sustained-release capsule ensures a gradual release of the drug, maintaining consistent plasma levels over a prolonged period.o Reduction in Dosage Frequency: Sustained-release capsules reduce the frequency of administration (usually to twice daily instead of thrice daily for immediate-release tablets).o Minimized Side Effects: A controlled release reduces the risk of peak plasma concentrations that can cause dose-related side effects, such as nausea or dizziness.Physicochemical and Pharmacokinetic Properties of Mebeverine

o	Short Half-Life:

Mebeverine has a relatively short half-life (~2 hours), which makes it ideal for sustained-release formulations to prolong its action.o Enhanced Patient Comfort: By avoiding frequent dosing, sustained-release formulations improve the quality of life for patients with chronic conditions like IBS.o Sensitive to First-Pass Metabolism: Mebeverine undergoes extensive first-pass metabolism, forming active metabolites.Sustained-release formulations help reduce fluctuations in drug levels and ensure a steady therapeutic effect.This choice is made to enhance its therapeutic efficacy and improve patient compliance.This increases convenience and adherence to the prescribed regimen.2.

The preferred solid dosage form for mebeverine is typically a sustained-release capsule. This choice is made to enhance its therapeutic efficacy and improve patient compliance. Here’s why this dosage form is preferred:

1. 
   

   Rationale for Sustained-Release Capsules

   
   

   • Controlled Release:
   Mebeverine is an antispasmodic used primarily for the treatment of irritable bowel syndrome (IBS) and other gastrointestinal disorders. A sustained-release capsule ensures a gradual release of the drug, maintaining consistent plasma levels over a prolonged period.
   • Reduction in Dosage Frequency:
   Sustained-release capsules reduce the frequency of administration (usually to twice daily instead of thrice daily for immediate-release tablets). This increases convenience and adherence to the prescribed regimen.
   • Minimized Side Effects:
   A controlled release reduces the risk of peak plasma concentrations that can cause dose-related side effects, such as nausea or dizziness.
   • Enhanced Patient Comfort:
   By avoiding frequent dosing, sustained-release formulations improve the quality of life for patients with chronic conditions like IBS.

   
   


2. 
   

   Physicochemical and Pharmacokinetic Properties of Mebeverine

   
   

   • Short Half-Life:
   Mebeverine has a relatively short half-life (~2 hours), which makes it ideal for sustained-release formulations to prolong its action.
   • Sensitive to First-Pass Metabolism:
   Mebeverine undergoes extensive first-pass metabolism, forming active metabolites. Sustained-release formulations help reduce fluctuations in drug levels and ensure a steady therapeutic effect.